论文部分内容阅读
目的探讨沙格列汀、阿卡波糖联合治疗老年2型糖尿病(初诊患者)的疗效。方法选取我院2015年2月~2016年2月收治的60例患者为研究对象,随机将患者分为观察组和对照组,两组各30例,对照组给予阿卡波糖治疗,观察组给予阿卡波糖联合沙格列汀治疗,比较两组的治疗效果。结果观察组空腹血糖(FPG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1c)发生率均低于对照组,差异显著,具有显著统计学意义(P<0.05)。结论沙格列汀联合阿卡波糖是治疗老年2型糖尿病的主要药物,安全性较高,值得推广应用。
Objective To investigate the effect of combination of saxagliptin and acarbose on senile type 2 diabetes mellitus (newly diagnosed). Methods Sixty patients in our hospital from February 2015 to February 2016 were selected as study subjects. Patients were randomly divided into observation group and control group, 30 cases in each group, acarbose control group, observation group Given acarbose combined with saxagliptin treatment, the treatment effect of the two groups were compared. Results The incidences of fasting blood glucose (FPG), postprandial 2h blood glucose (PBG) and HbA1c in observation group were significantly lower than those in control group, with significant difference (P <0.05). Conclusion Saxagliptin combined with acarbose is the main drug for the treatment of type 2 diabetes mellitus in elderly. It is safe and worthy of promotion.